TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03919071

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib Mesylate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT01777672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pharyngeal electrical stimulation
Description: Includes neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during 1 week, done at the same center.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical stimulation
Description: Trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.
Study: NCT03919071

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO
Study: NCT03131427

Intervention type: DRUG
Intervention: Standard of care
Description: Standard of care according to the updated national and/or international guidelines

Intervention type: DRUG
Intervention: Standard of care
Description: Standard of care according to the updated national and/or international guidelines

Intervention type: DRUG
Intervention: Standard of care
Description: Standard of care according to the updated national and/or international guidelines

Intervention type: DRUG
Intervention: Standard of care
Description: Standard of care according to the updated national and/or international guidelines

Intervention type: DRUG
Intervention: Standard of care
Description: Standard of care according to the updated national and/or international guidelines
Study: NCT00812266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan + cisplatin
Description: topotecan IV 2 mg/sqm d1-3 + cisplatin IV 50 mg/sqm d3 q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide + carboplatin
Description: Etoposide 120 mg/sqm IV d 1-3 + carboplatin AUC 5 d1 q3W
Study: NCT02687074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: patients treated with high flow nasal cannula

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV
Description: patients treated with noninvasive ventilation
Study: NCT03859466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Therapy
Description: The cardiac shockwave system consists of a table-top device (Nonvasiv Medical GmbH, Konstanz, Germany) and a sterile single-use applicator releasing electrohydraulic shockwaves (Heart Regeneration Technologies GmbH, Innsbruck, Austria). Prior to use, the applicator is inserted into a sterile cover containing ultrasound gel. In order to ensure acoustic coupling between the applicator and the myocardium, continuous saline rinsing is applied throughout the procedure.
Study: NCT00115726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide
Description: for patients on chronic furosemide therapy, patients are randomized to furosemide (at their previous dose) or placebo (given in identical form to ensure masking)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will be given placebo capsules (identical to experimental arm in color) at the equivalent dose as to their chronic furosemide therapy.
Study: NCT02649803

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: asthma APP
Description: Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the nearest community hospital or Shanghai Children's Medical Center, whichever is nearer to the subject's home, for their future onsite visits (V2-V5). The patient's caregiver will be instructed to install the asthma APP at their smart phone and learn how to use this APP.
Study: NCT04053348

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Home-based rehabilitation program using mobile app
Description: Home-based rehabilitation program

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program using mobile app
Description: Home-based rehabilitation program
Study: NCT01729377

Intervention type: OTHER
Intervention: Interview
Study: NCT00533273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collagenase clostridium histolyticum
Description: Subjects could have received up to three injections of AA4500 0.58 mg/placebo into the cord of the affected hand in the double-blind phase. In the open-label extension phase, subjects could have received up to five additional injections of AA4500, with each injection separated by at least 30 days. Individual joints could have received up to a maximum of three AA4500 injections.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: collagenase clostridium histolyticum
Description: Subjects could have received up to three injections of AA4500 0.58 mg/placebo into the cord of the affected hand in the double-blind phase. In the open-label extension phase, subjects could have received up to five additional injections of AA4500, with each injection separated by at least 30 days. Individual joints could have received up to a maximum of three AA4500 injections.
Study: NCT01168557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EIT (Electrical Impedance Tomography)
Description: EIT measurement; concomitant to stress echocardiography (about 45 minutes) EIT measurements (1 minute) are performed at rest, at low dobutamine stress, at peak and at relaxation
Study: NCT00662740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium/Salmeterol QD
Description: Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Salmeterol Inhalation Powder, hard PE capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium/Salmeterol QD+ Salmeterol
Description: Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium (Spiriva®)
Description: Tiotropium, Spiriva®
Study: NCT00262964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: Subjects randomized to Niacin therapy will be treated with Niacin at night for 16 wks to reduce plasma free fatty acid concentrations. The dose of medication will be gradually increased: 500 mg/day during week 1, 1000 mg/day during week 2, 1500 mg/day during week 3, and 2000mg/day during weeks 4-16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate
Description: Subjects randomized to fenofibrate will be treated with 200 mgs per day for eight weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects randomized to placebo will be treated with one placebo pill per day for eight weeks.
Study: NCT02996682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Capsules administered orally in a divided daily dose
Study: NCT01929642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study: NCT03843593

Intervention type: BEHAVIORAL
Intervention: Demographics Questionnaire
Description: A brief questionnaire will collect basic demographic information (i.e., age, gender, racial background, ethnicity, employment status, marital status) at time of enrollment.

Intervention type: BEHAVIORAL
Intervention: Adjuvant Treatment Beliefs Scale10
Description: This brief PRO measure asks patients to indicate the likelihood, using a 5-point Likert type scale (1 \[definitely not\], 2 \[probably not\], 3 \[maybe\], 4 \[probably\], 5 \[definitely\]) of six positive (e.g., reduced risk of recurrence, greater chance of being cured) and five negative outcomes (e.g., side effects, health status) of adjuvant treatment.

Intervention type: BEHAVIORAL
Intervention: Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11
Description: FACT-M is a 51-item patient-self report measure for the assessment of quality of life (QOL) in patients with American Joint Committee on Cancer stages I through IV melanoma.
Study: NCT02229422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA101/HDMP
Description: All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:~* On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.~* On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.~* On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.~* On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.~All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:~•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered.
Study: NCT02009241

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Study: NCT03843593

Intervention type: BEHAVIORAL
Intervention: Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13
Description: FACIT-TS-G is a brief, 8-item self-administered measure designed to assess general treatment satisfaction in patients.

Intervention type: BEHAVIORAL
Intervention: Decisional Regret14
Description: This is a set of 5 questions examining level of regret for treatment decisions (in this case, decision to pursue adjuvant therapy), with answers scored on a 5-point Likert-type scale (i.e., 1 \[Strongly Agree\], 2 \[Agree\], 3 \[Neither Agree Nor Disagree\], 4 \[Disagree\], 5 \[Strongly Disagree\].

Intervention type: BEHAVIORAL
Intervention: Clinician Preference for Treatment
Description: This is a single item to be completed by Medical Oncologists that will indicate their preference as to whether they prefer that their patient accepts adjuvant therapy.
Study: NCT00735904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: AG-013736 5 mg tablets orally, twice daily, until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m\^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles
Study: NCT02850419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThermoDox (Thermally Sensitive Liposomal Doxorubicin)
Description: A dose of 40 mg/m2 will be administered at each cycle for a total of 6 cycles. ThermoDox will be administered in conjunction with hyperthermia.
Study: NCT00735904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 1mg/ml solution or as lyophilized powder, to be administered as 80 mg/m\^2 IV infusion on Day 1 of 21-day cycle. For a maximum of 6 cycles
Study: NCT03333291

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fecal suspension
Description: helathy donor fecal suspension administered by duodenal scope
Study: NCT02850419

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: A total of 40 Gy in 20 fractions of 2 Gy per fraction will be administered. Up to 66 Gy of radiation therapy can be administered however institutional guidelines should be followed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Superficial Hyperthermia
Description: Thermal dose is an one-hour treatment at a temperature between 40 and 43 degrees Celsius at the target site.
Study: NCT03287180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Community Reinforcement Approach (A-CRA)
Description: The A-CRA is a modified version of the Community Reinforcement Approach for adolescents and transitional age youth. The A-CRA treatment protocol consists of nineteen procedures designed to promote positive behavior change directed towards prosocial activities and engagement in the individual's community. A community can include but is not limited to: social and peer activities, family interaction, and work or school environments. Some of the highlighted procedures include relapse prevention, sobriety sampling, problem solving, and communication skills. There are also combined parent/and or couples relationship sessions with the young adult. In the current study, 12-weeks of A-CRA treatment will be provided to the intervention group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combination of buprenorphine/naloxone 4/1
Description: Buprenorphine is a partial agonist at mu-opioid receptor, an antagonist at kappa-opioid receptor. Naloxone is an antagonist at the mu-opioid receptor. Buprenorphine/naloxone requires the use of an induction to avoid the risk of withdrawal. Participants are instructed not to use opioids for at least 10 hours prior to first dose. Once symptoms of withdrawal score a minimum of 7 on the Clinical Opiate Withdrawal Scale (COWS), the first dose of 4/1 mg will be given. Participants will be monitored for an hour. An additional 4/1 mg dose can be provided to a dose that suppresses withdrawal effects. The physician then provides a prescription for 8/2-16/4 mg for Day 2. Doses can be adjusted with a maximum of total 24/6 mg/day. The target daily dose is 16/4 mg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of buprenorphine/naloxone 4/1
Description: Buprenorphine is a partial agonist at mu-opioid receptor, an antagonist at kappa-opioid receptor. Naloxone is an antagonist at the mu-opioid receptor. Buprenorphine/naloxone requires the use of an induction to avoid the risk of withdrawal. Participants are instructed not to use opioids for at least 10 hours prior to first dose. Once symptoms of withdrawal score a minimum of 7 on the Clinical Opiate Withdrawal Scale (COWS), the first dose of 4/1 mg will be given. Participants will be monitored for an hour. An additional 4/1 mg dose can be provided to a dose that suppresses withdrawal effects. The physician then provides a prescription for 8/2-16/4 mg for Day 2. Doses can be adjusted with a maximum of total 24/6 mg/day. The target daily dose is 16/4 mg.
Study: NCT04285775

Intervention type: DEVICE
Intervention: Application of device which monitors for bleeding - Blood Warning Technology with Continuous Hemoglobin sensor (BWATCH)
Description: A stand-alone disc-shaped device (approximately 5 cm in diameter and \<1 cm thick) which can be placed over dressings. Once switched on and put in place, continuous monitoring for bleeding takes place. Detection occurs in 2 phases. First, the system monitors for the appearance of fluid in the dressing by detecting a change in capacitance. Next, a light sensor differentiates blood from other fluids by detecting that a unique spectrum of light (525nm) is absorbed, a property unique for hemoglobin. The presence of fresh blood triggers a loud alarm, alerting medical staff to attend to the patient. The device can be used over transparent plastic dressings and does not require direct contact with blood.

Intervention type: DEVICE
Intervention: Application of device which monitors for bleeding - Blood Warning Technology with Continuous Hemoglobin sensor (BWATCH)
Description: A stand-alone disc-shaped device (approximately 5 cm in diameter and \<1 cm thick) which can be placed over dressings. Once switched on and put in place, continuous monitoring for bleeding takes place. Detection occurs in 2 phases. First, the system monitors for the appearance of fluid in the dressing by detecting a change in capacitance. Next, a light sensor differentiates blood from other fluids by detecting that a unique spectrum of light (525nm) is absorbed, a property unique for hemoglobin. The presence of fresh blood triggers a loud alarm, alerting medical staff to attend to the patient. The device can be used over transparent plastic dressings and does not require direct contact with blood.
Study: NCT03030963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equal ratio ventilation(ERV)
Description: Set the inspiratory to expiratory ratio 1:1 during mechanical ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: I:E Ratio 1:2
Description: Set the inspiratory to expiratory ratio 1:2 during mechanical ventilation
Study: NCT02012530

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HA
Description: HA is widely applied in clinical practice with good results in many studies. HA forms part of the inflammatory process that can lead to the regeneration of cartilage in defective areas of the knee.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: PRP uses reparative growth factors taken from the patient's own blood to create an environment in the knee conducive to wound healing that can fill cartilage defects. It's autologous origin, easy preparation and safety profile makes it a potentially ground breaking treatment option for knee cartilage defects and osteoarthritis.
Study: NCT01675232

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soak and smear
Description: Corticosteroid ointment applied to wet skin once a day and dry skin once a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Smear
Description: Corticosteroid ointment applied to dry skin twice a day.
Study: NCT00819741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
Study: NCT00714571

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mnemonic strategy training (MST)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mnemonic strategy training (MST)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mnemonic strategy training (MST)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Repeated exposure (XP)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Repeated exposure (XP)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Subtracting Cues training
Study: NCT04514354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GEST
Description: On either Visit 3 or 4, subjects performed a maximal cardiopulmonary GEST following the Balke protocol. Immediately prior to the GEST, the study physician or his designee performed a brief physical examination, in which BP was assessed and all relevant medical information (i.e. medical history, medications, family history) were reviewed. The physician who completed the physical examination remained present during the GEST to monitor the subjects' electrocardiogram (ECG) and other physical signs. After the GEST was completed, the study physician reviewed the ECG for signs of ischemia. Breath-by-breath analysis of expired gases (i.e. oxygen and carbon dioxide) (ParvoMedicsTruneOne® 2400 Metabolic Measurement System, ParvoMedics Inc., Sandy, UT) determined maximal oxygen uptake (VO2max). Heart rate was measured continuously with a 12-lead ECG system and BP was measured by auscultation every 3 minutes during the GEST.
Study: NCT01210417

Intervention type: OTHER
Intervention: Non invasive monitoring
Description: Three-lead electrocardiogram (ECG), PPG oxymetry, non-invasive blood pressure (NIBP) are registered
Study: NCT01693172

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early mobilization program
Description: Early postoperative supervised aerobic exercise, resistance and flexibility training
Study: NCT00819741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: repaglinide
Description: The dose was started from repaglinide 1 mg three times daily. During the dose titration period, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose.
Study: NCT02419937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: 162 mg subcutaneously once (vs. 0.9% normal saline placebo injection once in placebo arm)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection
Study: NCT03389438

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous Tcm cells immunotherapy
Description: Autologous Tcm cells immunotherapy is to collect patient's own immune cells and infuse back into the patient's body after culture in vitro that can activate the anti-tumor immune response and achieve the purpose of cancer treatment.
Study: NCT00693966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1)
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2)
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3)
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-517 HPV-16/18 VLP with Al(OH)3 (Formulation 4)
Description: IM injection
Study: NCT04444557

Intervention type: OTHER
Intervention: Beck Depression Inventory (BDI)
Description: The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression

Intervention type: OTHER
Intervention: Beck Depression Inventory (BDI)
Description: The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression
Study: NCT04074174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-0833
Description: NNC0174-0833 administered s.c. (subcutaneously, under the skin) once weekly for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) tablets
Description: 1 tablet daily on days 1-8 and days 79-86

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Single dose of acetaminophen as part of a standardised meal on day 1 and day 79
Study: NCT04373278

Intervention type: OTHER
Intervention: failure of reconstruction of the mandibule by free fibula flap
Description: description of failure of reconstruction of the mandibule by free fibula flap:delay, type of bacteria involved in the failure, treatment, outcome